Updated with new information.

Sage Therapeutics (SAGE) reported positive results Thursday from two late-stage clinical trials of its lead drug brexanolone in women suffering from postpartum depression.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.